skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radioimmunoscintigraphy of non-small cell lung cancer using Tc-99m ANTI-CEA FAB` (immuRAID CEA)

Abstract

We conducted a Phase II prospective multicenter clinical trial to investigate the safety and efficacy of Tc-99M anti-CEA Fab`(ImmuRAID-CEA) in patients with non-small cell lung cancer. Fifty four patients (42 male; 12 female; age range 40-93 yr) had primary operable (19), primary inoperable (7), occult (9), metastatic (15) or recurrent (4) disease. Patients were injected with 1 mg ImmuRAID-CEA radiolabeled with 20-30 mCi Tc-99m pertechnetate and imaged at 4-8 and 18-24 hr by planar and SPECT techniques; ten were imaged at 15-18 hr only. Despite prominent blood pool activity at 4-8 hr. overall imaging statistics on a per patient basis revealed a sensitivity of tumor detection of 90%, accuracy 85% and positive predictive value 94%. The later images had lower count rates but target to background ratios were improved. On a per lesion basis, sensitivity in the chest was 69% and in liver 88%. Twenty four patients had additional foci of antibody uptake at sites previously believed to be uninvolved; cancer was confirmed in 11, not confirmed in 2 and currently indeterminate in 11. Furthermore, a negative scan confirmed equivocal radiographic studies as true negative in 5 patients. With respect to safety, there were no adverse clinical reactions and fourmore » minor, transient changes in hematologic and/or biochemical parameters. Human anti-mouse antibody (HAMA) determinations on 27 patients using ImmuSTRIP{reg_sign} HAMA Fragment assay were negative at 4-6 weeks or 3 months post-infusion. We conclude that imaging with ImmuRAID-CEA is safe and potentially useful for the evaluation and staging of lung cancer patients.« less

Authors:
 [1]; ;  [2]
  1. DVA Medical Center, Ann Arbor, MI (United States)
  2. Immunomedics Inc., Morris Plains, NJ (United States); and others
Publication Date:
OSTI Identifier:
198073
Report Number(s):
CONF-940605-
Journal ID: JNMEAQ; ISSN 0161-5505; TRN: 95:007029-0225
Resource Type:
Journal Article
Journal Name:
Journal of Nuclear Medicine
Additional Journal Information:
Journal Volume: 35; Journal Issue: Suppl.5; Conference: 41. annual meeting of the Society of Nuclear Medicine, Orlando, FL (United States), 5-8 Jun 1994; Other Information: PBD: May 1994
Country of Publication:
United States
Language:
English
Subject:
55 BIOLOGY AND MEDICINE, BASIC STUDIES; LUNGS; NEOPLASMS; ACCURACY; IMAGES; PATIENTS; RADIOIMMUNOSCINTIGRAPHY; STATISTICS; UPTAKE; TECHNETIUM 99; PERTECHNETATES

Citation Formats

Fig, L M, Hughes, L, and Pinsky, C M. Radioimmunoscintigraphy of non-small cell lung cancer using Tc-99m ANTI-CEA FAB` (immuRAID CEA). United States: N. p., 1994. Web.
Fig, L M, Hughes, L, & Pinsky, C M. Radioimmunoscintigraphy of non-small cell lung cancer using Tc-99m ANTI-CEA FAB` (immuRAID CEA). United States.
Fig, L M, Hughes, L, and Pinsky, C M. 1994. "Radioimmunoscintigraphy of non-small cell lung cancer using Tc-99m ANTI-CEA FAB` (immuRAID CEA)". United States.
@article{osti_198073,
title = {Radioimmunoscintigraphy of non-small cell lung cancer using Tc-99m ANTI-CEA FAB` (immuRAID CEA)},
author = {Fig, L M and Hughes, L and Pinsky, C M},
abstractNote = {We conducted a Phase II prospective multicenter clinical trial to investigate the safety and efficacy of Tc-99M anti-CEA Fab`(ImmuRAID-CEA) in patients with non-small cell lung cancer. Fifty four patients (42 male; 12 female; age range 40-93 yr) had primary operable (19), primary inoperable (7), occult (9), metastatic (15) or recurrent (4) disease. Patients were injected with 1 mg ImmuRAID-CEA radiolabeled with 20-30 mCi Tc-99m pertechnetate and imaged at 4-8 and 18-24 hr by planar and SPECT techniques; ten were imaged at 15-18 hr only. Despite prominent blood pool activity at 4-8 hr. overall imaging statistics on a per patient basis revealed a sensitivity of tumor detection of 90%, accuracy 85% and positive predictive value 94%. The later images had lower count rates but target to background ratios were improved. On a per lesion basis, sensitivity in the chest was 69% and in liver 88%. Twenty four patients had additional foci of antibody uptake at sites previously believed to be uninvolved; cancer was confirmed in 11, not confirmed in 2 and currently indeterminate in 11. Furthermore, a negative scan confirmed equivocal radiographic studies as true negative in 5 patients. With respect to safety, there were no adverse clinical reactions and four minor, transient changes in hematologic and/or biochemical parameters. Human anti-mouse antibody (HAMA) determinations on 27 patients using ImmuSTRIP{reg_sign} HAMA Fragment assay were negative at 4-6 weeks or 3 months post-infusion. We conclude that imaging with ImmuRAID-CEA is safe and potentially useful for the evaluation and staging of lung cancer patients.},
doi = {},
url = {https://www.osti.gov/biblio/198073}, journal = {Journal of Nuclear Medicine},
number = Suppl.5,
volume = 35,
place = {United States},
year = {Sun May 01 00:00:00 EDT 1994},
month = {Sun May 01 00:00:00 EDT 1994}
}